Japanese Drug Makers, Institute Develop Longer-Lasting Cultured Cells
This article was originally published in PharmAsia News
Executive Summary
Several Japanese drug makers and Japan's National Institute of Health Sciences have developed a new technique for preserving cultured cells for drug compatibility evaluation. Researchers from Astellas Pharma, Chugai Pharmaceutical, Kyowa Hakko Kogyo, Mitsubishi Tanabe Pharma, Nippon Shinyaku and Sanofi-Aventis KK joined the institute in the development. The technique they came up with extends the effective life of enzymes used by cells to metabolize drugs, eliminating the need to prepare and maintain new cell cultures for drug development efforts. (Click here for more - a subscription may be required
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.